MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals Operating Income 2011-2026 | ZYNE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.3 M | -36.8 M | -52.1 M | -34.3 M | -40.4 M | -32.8 M | -23.2 M | -12.5 M | -5.67 M | -634 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -634 K | -52.1 M | -27.4 M |
Quarterly Operating Income Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.1 M | -10.5 M | - | -8.49 M | -9.17 M | -8.9 M | - | -10.2 M | -9.84 M | -7.88 M | -10.2 M | -9.23 M | -21.8 M | -10.8 M | -11.4 M | -1.93 M | -11.5 M | -9.47 M | -8.05 M | -7.99 M | -12 M | -12.4 M | -8.2 M | -8.55 M | -8.37 M | -7.7 M | -6.68 M | -6 M | -6.28 M | -4.24 M | -5.42 M | -4 M | -1.63 M | -1.49 M | -1.4 M | -2.51 M | -1.51 M | -239 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -239 K | -21.8 M | -7.7 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
30.5 M | $ 40.9 | 0.91 % | $ 1.5 B | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.36 | 4.06 % | $ 61.3 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 24.44 | -4.12 % | $ 1.13 B | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 7.13 | -1.79 % | $ 624 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.65 | -1.22 % | $ 2.06 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.13 | 1.8 % | $ 122 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 1.2 | 9.09 % | $ 1.49 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.48 | 1.16 % | $ 86.3 M | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 6.16 | -1.28 % | $ 3.81 B | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.26 | 0.44 % | $ 305 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 5.33 | -1.11 % | $ 344 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.41 | 3.68 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.47 | 2.67 % | $ 434 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.57 | 9.36 % | $ 338 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.87 | 0.14 % | $ 3.75 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.47 | 0.22 % | $ 118 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.64 | 1.6 % | $ 302 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.99 | 6.48 % | $ 49.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
766 M | $ 15.04 | 0.67 % | $ 18.1 B | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.89 | 1.29 % | $ 32 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.53 | -2.39 % | $ 2.27 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.07 | 1.47 % | $ 23.9 M | USA |